These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35149777)
1. UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab. Lin N; Damask A; Boyapati A; Hamilton JD; Hamon S; Ternes N; Nivens MC; Penn J; Lopez A; Reid JG; Overton J; Shuldiner AR; Abecasis G; Baras A; Paulding C Pharmacogenomics J; 2022 May; 22(3):160-165. PubMed ID: 35149777 [TBL] [Abstract][Full Text] [Related]
2. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381 [TBL] [Abstract][Full Text] [Related]
3. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410 [TBL] [Abstract][Full Text] [Related]
4. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Lee JS; Wang J; Martin M; Germer S; Kenwright A; Benayed R; Spleiss O; Platt A; Pilson R; Hemmings A; Weinblatt ME; Kaplowitz N; Krasnow J Pharmacogenet Genomics; 2011 Jul; 21(7):365-74. PubMed ID: 21412181 [TBL] [Abstract][Full Text] [Related]
5. Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms. Mori S; Terada K; Ueki Y Mod Rheumatol; 2012 Aug; 22(4):515-23. PubMed ID: 21993917 [TBL] [Abstract][Full Text] [Related]
6. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis. Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351 [TBL] [Abstract][Full Text] [Related]
7. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. Lamb YN; Deeks ED Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592 [TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324 [TBL] [Abstract][Full Text] [Related]
9. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246 [TBL] [Abstract][Full Text] [Related]
10. A review of sarilumab for the treatment of rheumatoid arthritis. Lee EB Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871 [TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis. Ma L; Xu C; Paccaly A; Kanamaluru V Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251 [TBL] [Abstract][Full Text] [Related]
13. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216 [TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318 [TBL] [Abstract][Full Text] [Related]
15. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757 [TBL] [Abstract][Full Text] [Related]
16. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208 [TBL] [Abstract][Full Text] [Related]
17. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. June RR; Olsen NJ Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017 [TBL] [Abstract][Full Text] [Related]
18. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324 [TBL] [Abstract][Full Text] [Related]
19. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]